BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 16158274)

  • 1. Therapeutic efficacy of tumor-targeted IL2 in LTalpha(-/-) mice depends on conditioned T cells.
    Schrama D; Voigt H; Eggert AO; Xiang R; Reisfeld RA; Becker JC
    Cancer Immunol Immunother; 2006 Jul; 55(7):861-6. PubMed ID: 16158274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy.
    Becker JC; Pancook JD; Gillies SD; Furukawa K; Reisfeld RA
    J Exp Med; 1996 May; 183(5):2361-6. PubMed ID: 8642346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting activity of a TCR/IL-2 fusion protein against established tumors.
    Wen J; Zhu X; Liu B; You L; Kong L; Lee HI; Han KP; Wong JL; Rhode PR; Wong HC
    Cancer Immunol Immunother; 2008 Dec; 57(12):1781-94. PubMed ID: 18369620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological tumor destruction in a murine melanoma model by targeted LTalpha independent of secondary lymphoid tissue.
    Schrama D; Voigt H; Eggert AO; Xiang R; Zhou H; Schumacher TN; Andersen MH; thor Straten P; Reisfeld RA; Becker JC
    Cancer Immunol Immunother; 2008 Jan; 57(1):85-95. PubMed ID: 17605009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy.
    Winter H; Hu HM; McClain K; Urba WJ; Fox BA
    J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells.
    Poehlein CH; Hu HM; Yamada J; Assmann I; Alvord WG; Urba WJ; Fox BA
    J Immunol; 2003 Feb; 170(4):2004-13. PubMed ID: 12574370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphotoxin-alpha-deficient mice make delayed, but effective, T and B cell responses to influenza.
    Lund FE; Partida-Sánchez S; Lee BO; Kusser KL; Hartson L; Hogan RJ; Woodland DL; Randall TD
    J Immunol; 2002 Nov; 169(9):5236-43. PubMed ID: 12391242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy.
    Pretto F; Elia G; Castioni N; Neri D
    Cancer Immunol Immunother; 2014 Sep; 63(9):901-10. PubMed ID: 24893857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
    Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
    J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy.
    Neal ZC; Yang JC; Rakhmilevich AL; Buhtoiarov IN; Lum HE; Imboden M; Hank JA; Lode HN; Reisfeld RA; Gillies SD; Sondel PM
    Clin Cancer Res; 2004 Jul; 10(14):4839-47. PubMed ID: 15269160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type 1 and type 2 CD8+ effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor.
    Dobrzanski MJ; Reome JB; Dutton RW
    J Immunol; 2000 Jan; 164(2):916-25. PubMed ID: 10623840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy.
    Imboden M; Murphy KR; Rakhmilevich AL; Neal ZC; Xiang R; Reisfeld RA; Gillies SD; Sondel PM
    Cancer Res; 2001 Feb; 61(4):1500-7. PubMed ID: 11245457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins.
    Becker JC; Pancook JD; Gillies SD; Mendelsohn J; Reisfeld RA
    Proc Natl Acad Sci U S A; 1996 Apr; 93(7):2702-7. PubMed ID: 8610104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFα Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma.
    Tähtinen S; Blattner C; Vähä-Koskela M; Saha D; Siurala M; Parviainen S; Utikal J; Kanerva A; Umansky V; Hemminki A
    J Immunother; 2016; 39(9):343-354. PubMed ID: 27741089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mice with a targeted mutation in lymphotoxin-alpha exhibit enhanced tumor growth and metastasis: impaired NK cell development and recruitment.
    Ito D; Back TC; Shakhov AN; Wiltrout RH; Nedospasov SA
    J Immunol; 1999 Sep; 163(5):2809-15. PubMed ID: 10453025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetically modified murine adipose-derived mesenchymal stem cells producing interleukin-2 favor B16F10 melanoma cell proliferation.
    Bahrambeigi V; Ahmadi N; Salehi R; Javanmard SH
    Immunol Invest; 2015; 44(3):216-36. PubMed ID: 25565576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor.
    Kjaergaard J; Peng L; Cohen PA; Drazba JA; Weinberg AD; Shu S
    J Immunol; 2001 Dec; 167(11):6669-77. PubMed ID: 11714839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma.
    Hirschowitz EA; Leonard S; Song W; Ferris B; Leopold PL; Lewis JJ; Bowne WB; Wang S; Houghton AN; Crystal RG
    Gene Ther; 1998 Jul; 5(7):975-83. PubMed ID: 9813669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade.
    Drerup JM; Deng Y; Pandeswara SL; Padrón ÁS; Reyes RM; Zhang X; Mendez J; Liu A; Clark CA; Chen W; Conejo-Garcia JR; Hurez V; Gupta H; Curiel TJ
    Cancer Res; 2020 Nov; 80(22):5063-5075. PubMed ID: 32948605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratumoral immunocytokine treatment results in enhanced antitumor effects.
    Johnson EE; Lum HD; Rakhmilevich AL; Schmidt BE; Furlong M; Buhtoiarov IN; Hank JA; Raubitschek A; Colcher D; Reisfeld RA; Gillies SD; Sondel PM
    Cancer Immunol Immunother; 2008 Dec; 57(12):1891-902. PubMed ID: 18438664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.